^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

INBRX-106

i
Other names: ES 102, INBRX106, INBRX 106, INBRX-106, ES102, ES-102
Associations
Company:
Elpiscience, Inhibrx Biosci
Drug class:
OX40 agonist
Associations
2ms
New P2 trial
|
Loqtorzi (toripalimab-tpzi) • INBRX-106
2ms
Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients (clinicaltrials.gov)
P2, N=12, Recruiting, Providence Health & Services | Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2026 --> Jun 2027
Enrollment open • Trial primary completion date • Combination therapy
|
Keytruda (pembrolizumab) • INBRX-106
4ms
Combination therapy • Phase classification • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • INBRX-106
6ms
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC (clinicaltrials.gov)
P2/3, N=410, Recruiting, Inhibrx, Inc. | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • INBRX-106
7ms
A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=18, Completed, Elpiscience Biopharma, Ltd. | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Mar 2024
Trial completion • Trial completion date • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK rearrangement
|
INBRX-106
8ms
New P2 trial • Combination therapy
|
Keytruda (pembrolizumab) • INBRX-106
9ms
New P2/3 trial • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • INBRX-106
9ms
A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=18, Active, not recruiting, Elpiscience Biopharma, Ltd. | Trial completion date: Mar 2024 --> Jun 2024
Trial completion date • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK rearrangement
|
INBRX-106
9ms
Combination therapy • Phase classification • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
|
EGFR mutation • TMB-H • MSI-H/dMMR • ALK rearrangement
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • INBRX-106
over1year
Combination therapy • Enrollment change • Phase classification
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
|
EGFR mutation • TMB-H • MSI-H/dMMR • ALK rearrangement
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • INBRX-106
almost2years
Combination therapy • Trial completion date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
|
EGFR mutation • TMB-H • MSI-H/dMMR • ALK rearrangement
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • INBRX-106
2years
A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=18, Active, not recruiting, Elpiscience Biopharma, Ltd. | N=36 --> 18 | Trial completion date: Dec 2022 --> Mar 2024 | Trial primary completion date: Sep 2022 --> Dec 2023
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK rearrangement
|
INBRX-106
almost3years
Combination therapy • Trial completion date • Trial primary completion date • Enrollment change
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK rearrangement
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • INBRX-106
3years
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=146, Recruiting, Elpiscience Biopharma, Ltd. | Not yet recruiting --> Recruiting
Clinical • Enrollment open • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK rearrangement
|
Loqtorzi (toripalimab-tpzi) • INBRX-106
over3years
Clinical • New P1 trial • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK rearrangement
|
Loqtorzi (toripalimab-tpzi) • INBRX-106
over3years
A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=36, Recruiting, Elpiscience Biopharma, Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK rearrangement
|
INBRX-106
almost4years
Clinical • New P1 trial
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK rearrangement
|
INBRX-106